弥合儿童及青少年霍奇金淋巴瘤的生存者差距
本文综述儿童及青少年霍奇金淋巴瘤治疗早期成功但无病生存不反映远期器官损伤与健康相关生活质量(HRQoL)的问题。作者提出「生存者差距」概念,从一级预防(调整治疗)和二级预防(干预远期效应)框架阐述弥合差距的方向。
要点
- 儿童青少年霍奇金淋巴瘤短期无病生存与长期健康及HRQoL存在不一致,即生存者差距。
- 一级预防旨在调整治疗以维持无病生存同时减少远期效应。
- 二级预防侧重对远期效应进行干预,需关注肿瘤生物学、微环境、宿主遗传及HRQoL。
核心结论
- 儿童及青少年霍奇金淋巴瘤治疗早期成功,但无病生存不反映5年后的潜在器官损伤及其对健康状况和福祉的影响。
- 短期无淋巴瘤生存与长期健康和HRQoL之间的不一致构成「生存者差距」,可在个体和患者亚组中刻画。
- 弥合生存者差距需要增强对肿瘤和微环境生物学、宿主遗传因素、HRQoL及结局差异亚群的认识和关注。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 过早发病和死亡导致该年轻诊断人群潜在生产力生命年数相关的高社会成本。
- 生存者差距可从一级预防和二级预防两个框架来理解。
- 一级预防旨在调整治疗,二级预防 entails 针对远期效应的干预策略。
临床怎么用
- 临床需在维持无病生存的同时个体化治疗以减少远期效应并保护HRQoL。
- 应关注肿瘤生物学、微环境、宿主遗传因素及HRQoL以识别结局差异亚群。
局限性
- 本文为综述,摘要未报告系统检索范围及具体研究样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of Hodgkin lymphoma (HL) is one of early success. However, disease-free survival (DFS) does not reflect latent organ injury and its impact on health status and well-being beyond 5 years. In fact, we are at a crossroads, in terms of needing individualized approaches to maintain DFS, while minimizing late effects and preserving health-related quality of life (HRQoL). Premature morbidity and mortality translate to a high societal cost associated with the potential number of productive life years ahead in this population who are young at diagnosis. The discordance between short-term lymphoma-free survival and long-term health and HRQoL creates a "survivorship gap" which can be characterized for individuals and for subgroups of patients. The current review delineates contributors to compromised outcomes and health status in child and adolescent (paediatric) HL and frames the survivorship gap in terms of primary and secondary prevention. Primary prevention aims to titrate therapy. Secondary prevention entails strategies to intervene against late effects. Bridging the survivorship gap will be attained with enhanced knowledge of and attention to biology of the tumour and microenvironment, host genetic factors, HRQoL and sub-populations with disparate outcomes.
引用
- Castellino SM, Parsons SK, Kelly KM, et al. Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. Br J Haematol. 2019. PMID: 31566730. doi:10.1111/bjh.16197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。